Serotonin-Induced Hypersensitivity via Inhibition of Catechol O-Methyltransferase Activity
© Tsao et al.; licensee BioMed Central Ltd. 2012
Received: 12 January 2012
Accepted: 27 March 2012
Published: 13 April 2012
The subcutaneous and systemic injection of serotonin reduces cutaneous and visceral pain thresholds and increases responses to noxious stimuli. Different subtypes of 5-hydroxytryptamine (5-HT) receptors are suggested to be associated with different types of pain responses. Here we show that serotonin also inhibits catechol O-methyltransferase (COMT), an enzyme that contributes to modultion the perception of pain, via non-competitive binding to the site bound by catechol substrates with a binding affinity comparable to the binding affinity of catechol itself (K i = 44 μM). Using computational modeling, biochemical tests and cellular assays we show that serotonin actively competes with the methyl donor S-adenosyl-L-methionine (SAM) within the catalytic site. Binding of serotonin to the catalytic site inhibits the access of SAM, thus preventing methylation of COMT substrates. The results of in vivo animal studies show that serotonin-induced pain hypersensitivity in mice is reduced by either SAM pretreatment or by the combined administration of selective antagonists for β2- and β3-adrenergic receptors, which have been previously shown to mediate COMT-dependent pain signaling. Our results suggest that inhibition of COMT via serotonin binding contributes to pain hypersensitivity, providing additional strategies for the treatment of clinical pain conditions.
Catechol O-methyltransferase (COMT) is an enzyme that has been implicated in the perception of mechanical, thermal, and inflammatory pain in both humans and rodents [1–3]. Its association with a broad range of noxious stimuli suggests its critical role as an underlying factor for the fundamental processes of pain perception. The enzymatic activity of COMT is reversely correlated with the intensity of perceived pain; higher levels of COMT activity correspond to lower pain sensitivity [1–4]. Thus, compounds or cellular regulatory factors that lower COMT activity enhance pain sensation.
While commonly associated with antinociception [5, 6], serotonin (5-hydroxytryptamine, or 5-HT) is also known to produce a hyperalgesic response when injected subcutaneously or into deep tissue [7, 8]. Different subtypes of 5-HT receptors are associated with hypersensitive responses to various noxious stimuli. For example, mechanical hypersensitivity (allodynia) induced by serotonin has been linked to 5-HT1A, 5-HT2B, and 5-HT2C receptors [7, 9], whereas the 5-HT2A receptor appears to be responsible for 5-HT-induced thermal hypersensitivity .
Serotonin Binds to COMT
Binding interactions between serotonin and COMT were determined through surface plasmon resonance (Figure 1B) whereby both the rate of association (k on) and dissociation (k off) can be determined. We find that serotonin dissociates from COMT with a k off rate of 0.0012 s-1, and binds to COMT with a k on rate of 13.7404 M-1 s-1. The equilibrium dissociation constant (K D) was determined by dividing the dissociation rate from the association rate, and calculated to be 87 μM.
Serotonin Computationally Docks to the COMT Active Site
Next, we investigated whether serotonin could be accommodated within the catalytic site of COMT. Using computational docking tools [12, 13], we dock serotonin to an apo-COMT protein to predict its native pose in the active site. We find that serotonin occupies a site within the pocket that sterically overlaps with the binding site of SAM (Figure 1)C. In the crystal structure of holo-COMT, His142 participates in an edge-to-face interaction with the adenosine of SAM . However, during serotonin binding, His142 donates a hydrogen bond with the amine side chain of serotonin (Figure 1D). Another hydrogen bonding interaction takes place with the serotonin amine and the side chain carboxyl group of Asp90. These two residues are responsible for positioning serotonin near the binding pocket of SAM, thereby preventing SAM from accessing its site. The carbonyl backbone of His142 also accepts a hydrogen bond from the hydroxyl group of serotonin.
Two more residues form hydrogen-bonding interactions with serotonin. The carbonyl of Met40 forms a hydrogen bond with the imidazole group of serotonin, while Lys144 forms a hydrogen bond with the hydroxyl group of serotonin. The side chain of Met40 also packs against the indole ring of serotonin. Overall, the results of this docking simulation suggest that serotonin may inhibit COMT activity by preventing the binding of the critical cofactor, SAM.
Serotonin Inhibits COMT Activity
We examined the kinetics of the observed inhibition in a set of experiments using a two-site Michaelis-Menten model (see Materials and Methods; Figure 2D). The Michaelis-Menten equilibrium constants for catechol binding were determined when serotonin was absent or present (100 μM) to provide the calculated values or the apparent K M and K M,app (see Materials and Methods). A comparison of the calculated K M (16 μM) and K M,app (18.5 μM) values shows a negligible difference between their affinities towards the catechol substrate. However, a comparison of the maximum velocities reveals a greater difference. The V max in the absence of serotonin was 16 nM/min while the apparent V max,app in the presence of serotonin was 7 nM/min, suggesting that serotonin inhibition is non-competitive with respect to catechol.
Given the differences between V max and V max,app, we can calculate the inhibition constant for serotonin (apparent K i, or K i,app; see Materials and Methods). We find that K i,app is 44 μM, which is within the vicinity of our approximate K D determined via SPR (~87 μM). Overall, our results show that serotonin binds to COMT and inhibits its activity at a concentration that is similar to endogenous COMT substrates (~0.5 M intravesicular concentration; 25 μM reported for dopamine and ~10 μM for norepinephrine) [15–19].
Serotonin-Induced Hypersensitivity is Diminished by Pretreatment with SAM or β2/3 Antagonists
If serotonin inhibition of COMT occurs through the competitive binding of the active site with SAM to produce pain hypersensitivity, we would predict that the administration of SAM should antagonize serotonin-induced hypersensitivity. We tested this hypothesis by performing a series of standard in vivo nociceptive assays in mice featuring the intraplantar (i.pl.) administration of serotonin . We chose to use mechanical allodynia to assess the 5-HT-COMT interaction over the thermal pain, as thermal hyperalgesia is a far less important clinical symptom than mechanical allodynia, being observed in a much smaller percentage of chronic pain patients, being rated as much less bothersome, and having lower correlations with global pain ratings [20–22].
As an additional approach to examine whether a COMT is associated with serotonin-induced hypersensitivity, we determined whether the blockade of downstream receptors known to mediate COMT–dependent changes diminishes serotonin-induced hypersensitivity. Since we have previously shown that low COMT activity leads to increased pain sensitivity via a β2/3-adrenergic mechanism, blocking β2 and β3 adrenergic receptors should reduce the serotonin-induced hypersensitivity if that sensitivity is COMT-mediated . Again, serotonin produced robust hypersensitivity compared to saline-treated controls (p < 0.001; Figure 3B). Consistent with our hypothesis, we find that relative to serotonin administration alone, co-administration of ICI118,551 and SR59230A—compounds that respectively block β2 and β3 adrenergic receptors—significantly reduces serotonin hypersensitivity (p = 0.01; Figure 3B).
Thus, the results of our behavioral experiments are consistent with our in vitro and in silico results, and suggest that at least a portion of serotonin-induced hypersensitivity is mediated by a COMT → β2/β3 adrenergic receptor mechanism. Furthermore, our results indicate that serotonin can actively compete with SAM for the catalytic site of COMT.
Biochemical Interactions of Serotonin and COMT
Using binding and activity assays, we show that serotonin interacts with COMT in a manner that inhibits enzymatic activity. We estimate that the COMT’s KD for serotonin is approximately 87 μM, as determined with surface plasmon resonance experiments. Based on previous literature, our calculated K D of 87 μM for serotonin is a reasonable [15–19]. SAM has the lowest K D reported among COMT ligands, with a K D of 20.2 μM . In contrast, many common COMT catechol substrates exhibited dissociation constants in the range of 40 – 400 μM . The higher dissociation constants observed for COMT substrates is most likely a consequence of its low substrate specificity. The binding site for catechol is very solvent accessible and thus can accommodate a large array of ligands . Although COMT does not methylate most phenols or gallols , virtually all catechols are susceptible to methylation including bulkier steroid compounds. Thus, given a K D for serotonin that is of the same order of magnitude observed for other known substrates, the interaction between serotonin and COMT is very plausible within cells that contain COMT.
We also find that the activity of COMT is reduced in the presence of serotonin, with a K i of approximately 44 μM. Furthermore, our data suggest that serotonin is a non-competitive inhibitor with respect to catechol substrates. These results are in line with our structural model because serotonin occupies a region within the active site that appears to hinder SAM binding and still allows catechol binding from a steric viewpoint. Moreover, serotonin does not possess a methyl group to donate that would substitute for SAM binding.
COMT Contributes to Serotonin-Induced Hypersensitivity
Our in silico models and in vitro results suggest that serotonin is an inhibitor of COMT. However, whether this inhibition has biological significance cannot be ascertained from these data alone. Our structural model suggests that serotonin inhibits COMT activity by actively competing with SAM at the active site. This mechanism is further supported by our kinetics studies. We performed behavioral experiments to determine if our in silico model and in vitro data are predictive of in vivo effects on pain behaviors. Mice pretreated with SAM displayed diminishes serotonin-induced mechanical hypersensitivity (Figure 3A). We hypothesize that the additional SAM produces this attenuation by decreasing the probability of serotonin occupying the active site of COMT. The relatively modest anti-allodynic effect is most likely due to the limited half-life of SAM . The donating methyl group resides within a sulfonium center that is unstable due to its cationic charge. In addition, each SAM molecule can only donate one methyl group to a substrate. Once methylation occurs, SAM is converts into S-adenosyl-L-homocysteine (SAH). SAH can further serve as an inhibitor of COMT activity due to the high structural similarity to SAM but like serotonin, SAH is without a methyl donor .
SAM is a cofactor that is responsible for many methylation reactions within the cell. The behavioral effects of SAM found presently could be non-specific, and not mediated only by COMT. Thus, we examined whether serotonin enhances pain sensitivity via the downstream stimulation of a β2/3-adrenergic receptors as occurs in response to the pharmacological inhibition of COMT. Inhibiting COMT, and thereby preventing methylation of epinephrine and norepinephrine, promotes pain signaling through the stimulation of β2 and β3 receptors . If serotonin inhibits COMT in vivo, we would thus expect that the observed increases in pain sensitivity results, at least in part, from the activation of β2/3 receptors. Consistent with this view, blockade of β2/3 receptors inhibited serotonin-induced pain hypersensitivity in mice (Figure 3B).
Implications for Serotonin-Induced Hypersensitivity and SSRIs
Our current results are of potentially substantial clinical significance. Increasing the bioavailability of serotonin with selective serotonin reuptake inhibitors (SSRIs) produces analgesia in some animal models [6, 26] and can be used to treat clinical pain conditions [27, 28]. However, SSRIs show relatively low analgesic efficacy in patients suffering from persistent pain conditions such as fibromyalgia, rheumatoid arthritis, and migraines  [29–31] and have not gained widespread use for the treatment of persistent pain conditions [32–35]. In contrast, agents that have greater effects on the inhibition of norepinephrine relative serotonin reuptake (SNRIs), like duloxetine and milnacipran, show greater effect sizes and are more widely used for the treatment of a number of persistent pain states [36–38].
The clinical analgesic effects of SSRIs are very modest and do not match the expectations seen in animal models. Furthermore, several animal studies note a dual role for serotonin in both analgesia and hypersensitivity, which appears to be dependent on the model and site of administration. Thus, the unraveling of the neural mechanisms that underlie the dual action of serotonin on pain perception is of importance. Mechanisms proposed to date that explain the dual action of serotonin primarily involve the activation of different subpopulations of 5-HT receptors that are distributed at different anatomical locations [7–10]. Our in silico, in vitro and in vivo results suggest that serotonin’s pain-promoting effect can also at least in part be attributed to serotonin-dependent COMT inhibition. This finding opens a new avenue for increasing the analgesic efficacy of SSRIs by co-administrating SAMe and/or non-selective beta-blockers like propranolol.
While several 5-HT receptors subtypes are known to contribute to pain perception, we have demonstrated that 5-HT action on COMT activity is another mechanism underlying 5-HT induced hypersensitivity, through a non-competitive binding process between SAM and serotonin at COMT’s catalytic site. Elucidation of the mechanisms of serotonin-induced hypersensitivity will contribute to the further understanding of its pharmacodynamics, and may lead to the future development of new and effective serotonin-based treatments for human pain conditions.
Materials and methods
Docking Simulations of Serotonin to COMT Active Site
We employ the MedusaDock package to generate possible ligand conformations within the protein active site, and utilize the MedusaScore package to evaluate each conformation generated by MedusaDock [12, 13]. MedusaDock enables flexible docking of both the ligand and the side-chain amino acids of the protein. We perform all ligand docking simulations using the crystal structure of human COMT (PDB: 3BWM) .
Prior to all docking simulations, we first stripped all crystallized ligands bound to COMT. Crystallographic waters that were in the active site were retained for our docking simulations. We performed 200 docking simulations for serotonin, where each simulation began with a different seed number and each conformation generated from a simulation was subsequently minimized. All conformations were then ranked according to their free energy value. The lowest energy structure is determined to be the native pose.
Binding Measurements using Surface Plasmon Resonance
Purified COMT protein (derived from porcine liver) and serotonin ligand were obtained from Sigma-Aldrich. Protein concentration was verified by performing a BCA assay (Thermo Scientific). Purified COMT was biotinylated at its surface lysine residues using EZ-Link NHS-LC-LC Biotin (Thermo Scientific) at a 1:1 mole ratio of biotinylating reagent to protein and subsequently purified using a 1 mL Sephadex G-25 medium spin column. Biotinylated COMT was buffered with 10 mM Tris pH 7.4, 1 mM MgCl2, 1 μM DTT and stored at 4°C until use.
Surface plasmon resonance (SPR) measurements were conducted at 25°C using a Biacore 2000 instrument with a previously established protocol . Biotinylated COMT was first loaded onto a streptavidin-coated flow cell (sensor chip SA or Biotin CAPture Kit, GE Healthcare) at a flow rate of 5 μL/min, followed by a buffer flow, introduction of serotonin (buffered in 10 mM Tris pH 7.4, 1 mM MgCl2, 1 μM DTT), and then a final wash with buffer (10 mM Tris pH 7.4, 1 mM MgCl2, 1 μM DTT). Here the flow rate was established at 5 μL/min.
Radiolabeled SAM Activity Assay
Activity of COMT was measured through a series of experiments where the enzyme was incubated with the substrate catechol (dissolved in H2O, Fisher Scientific) and S-[methyl-3 H]-adenosyl-L-methionine (PerkinElmer, 10.0 Ci/mmol) . Reactions were carried out in a buffer containing 10 mM Tris (pH 7.4), 1 mM MgCl2, and 1 μM DTT with a total reaction volume of 100 μL.
To determine the linear range of the activity assay, SAM concentration (1 μM) was held constant while COMT concentration was varied (10 – 80 ng/μL). Each reaction was placed in a clean PCR tube and incubated at 37°C for 30 minutes. After incubation, reactions were terminated by addition of 100 μL of 1 M HCl to each tube. Radiolabeled catechol products were extracted from the reaction by adding 10 mL of scintillation fluid (MonoFlow I, National Diagnostics) and quantified using a scintillation counter. Activities were normalized for each reaction by performing a duplicate reaction with the COMT inhibitor, OR-486 (0.5 mg of inhibitor dissolved in 30 μL DMSO and 20 μL of 0.9% saline; OR-486 buffer alone does not inhibit reaction), and subtracting its radioactivity. We found that the linear range was between 10 and 40 ng/μL, and thus for all subsequent experiments we used a COMT concentration of 20 ng/μL.
Kinetic experiments were performed at a variety of catechol concentrations (0, 0.5, 1, 3.3, 5, 10, and 33 μM) while maintaining constant SAM (1 μM) and COMT (20 ng/μL) concentrations. Reactions were set-up for a variety of time points: 0, 5, 10, 30, 60, and 120 minutes. Each time-point reaction is incubated at 37°C and then quenched with 1 M HCl at its specified time point. Products were quantified as discussed above. Serotonin-inhibition experiments were conducted for the same catechol concentrations, but with the addition of 100 μM of serotonin (Sigma) to each reaction.
where Vmax,app is the apparent Vmax for the serotonin-inhibited curve.
Mouse Behavioral Experiments
Subjects were naïve, young adult (6–14 weeks old) outbred CD-1® (ICR:CrI) mice of both sexes (Charles River, Boucherville, QC). Animals were housed in groups of 2 to 6 with same-sex littermates, with food (Harlan Teklad 8604) and tap water available ad lib. Approximately equal numbers of male and female mice were used; no sex differences were noted so data from both sexes were pooled. All procedures followed the guidelines and regulations of the Canadian Council on Animal Care, and were approved by the McGill Downtown Animal Care and Use Committee.
Mechanical sensitivity was measured using the automated von Frey test. Mice were placed in individual transparent Plexiglas cubicles set atop a perforated metal floor (with 5-mm diameter holes 7 mm apart), and separated from each other by opaque dividers. Prior to testing, the mice were habituated to their surroundings for 1 h. A von Frey fiber with automatically increasing force (Ugo Basile Dynamic Plantar Aesthesiometer) was applied to the mid-plantar hind paw. Three separate withdrawal threshold determinations (on each hind paw) were taken at baseline (pre-injection) and then averaged. One withdrawal threshold determination (on each hind paw) was taken at every post-injection time point.
For the SAM pre-treatment study, after measuring baseline thresholds, mice received i.p. injections of S- (5’-Adenosyl)-L-methionine chloride (80 mg/kg) (Sigma), followed, 15 min later, by 20 μl i.pl. injections of serotonin hydrochloride (10 uM) (Sigma). Mice were tested at 15, 30, 45, 60, 90, 120, 180 and 240 min following the serotonin injection.
For the β-adrenergic antagonist study, mice received 20 μL i.pl. injections of serotonin hydrochloride (5 uM), followed, 15 min later, by i.p. injection of a cocktail of ICI118,551 (5 mg/kg) and SR59230A (50 mg/kg) (Tocris). Mice were tested at 15, 30, 45, 60, 90, 120, 180 and 240 min following the antagonist injection.
Pain hypersensitivity was quantified as the area over the time-threshold curve (post-injection), using the trapezoidal method.
We utilize Generalized Estimating Equations (GEE) to determine whether SAM pretreatment or co-administration of SR and ICI treatment versus serotonin alone resulted in significantly different paw withdrawal thresholds  across the repeated measurements. The response was the repeated measurements of paw withdrawal threshold at fixed intervals post-administration of treatment. This model included an intercept and a binary covariate reflecting treatment status (e.g., ICI118,551 and SR59230A treatment versus serotonin alone) as the only covariate, where parameter estimates for this covariate can be interpreted as the overall mean change over measurements in PWT due to treatment. We assume an AR correlation structure between repeated measurements, gaussian distribution of the data, and the identity link. We tested whether the estimate for our binary covariate for treatment was significantly different from zero (indicating a significant change in paw withdrawal threshold due to treatment effect) using Proc Genmod in SAS version 9.2, and report p-values from this test. We also report the estimated mean change in paw withdrawal threshold due to treatment effect ± the standard error of the mean change.
DT performed the in silico simulations, SPR experiments, COMT activity assays, and wrote the paper. J.S.W. performed the mouse model studies and wrote the paper. N.R. performed the GEE analysis and wrote the paper. R.E.S. performed mouse model studies. R.L.R. performed SPR experiments. S.K.S. developed the COMT activity assay. J.S.M. designed the mouse model experiments and wrote the paper. W.M. conceived of the hypothesis, designed the activity assay experiments, and wrote the paper. N.V.D. designed the in silico experiments, developed the hypothesis, and wrote the paper. L.D. designed the activity assay experiments, developed the hypothesis, and wrote the paper.
This work was supported by the US National Institutes of Health grant (R01GM080742 to N.V.D.); American Recovery and Reinvestment Act supplements (GM080742-03 S1, GM066940-06 S1 to N.V.D.x; National Institute of Dental and Craniofacial Research and National Institute of Neurological Disorders and Stroke grants (RO1-DE16558, UO1-DE017018, PO1 NS045685 to L.D. and W.M.).
- Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, et al.: Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005, 14: 135–143.View ArticlePubMedGoogle Scholar
- Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W: Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 2007, 128: 199–208. 10.1016/j.pain.2006.09.022View ArticlePubMedGoogle Scholar
- Segall SK, Nackley AG, Diatchenko L, Lariviere WR, Lu X, Marron JS, Grabowski-Boase L, Walker JR, Slade G, Gauthier J, et al.: Comt1 genotype and expression predicts anxiety and nociceptive sensitivity in inbred strains of mice. Genes Brain Behav 2010, 9: 933–946. 10.1111/j.1601-183X.2010.00633.xPubMed CentralView ArticlePubMedGoogle Scholar
- Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L: Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314: 1930–1933. 10.1126/science.1131262View ArticlePubMedGoogle Scholar
- Schul R, Frenk H: The role of serotonin in analgesia elicited by morphine in the periaqueductal gray matter (PAG). Brain Res 1991, 553: 353–357. 10.1016/0006-8993(91)90849-QView ArticlePubMedGoogle Scholar
- Roberts MH: 5-Hydroxytryptamine and antinociception. Neuropharmacology 1984, 23: 1529–1536. 10.1016/0028-3908(84)90097-2View ArticlePubMedGoogle Scholar
- Taiwo YO, Levine JD: Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 1992, 48: 485–490. 10.1016/0306-4522(92)90508-YView ArticlePubMedGoogle Scholar
- Sufka KJ, Schomburg FM, Giordano J: Receptor mediation of 5-HT-induced inflammation and nociception in rats. Pharmacol Biochem Behav 1992, 41: 53–56. 10.1016/0091-3057(92)90058-NView ArticlePubMedGoogle Scholar
- Lin SY, Chang WJ, Lin CS, Huang CY, Wang HF, Sun WH: Serotonin receptor 5-HT2B mediates serotonin-induced mechanical hyperalgesia. J Neurosci 2011, 31: 1410–1418. 10.1523/JNEUROSCI.4682-10.2011View ArticlePubMedGoogle Scholar
- Tokunaga A, Saika M, Senba E: 5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery. Pain 1998, 76: 349–355. 10.1016/S0304-3959(98)00066-9View ArticlePubMedGoogle Scholar
- Mannisto PT, Kaakkola S: Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999, 51: 593–628.PubMedGoogle Scholar
- Yin S, Biedermannova L, Vondrasek J, Dokholyan NV: MedusaScore: an accurate force field-based scoring function for virtual drug screening. J Chem Inf Model 2008, 48: 1656–1662. 10.1021/ci8001167PubMed CentralView ArticlePubMedGoogle Scholar
- Ding F, Yin S, Dokholyan NV: Rapid flexible docking using a stochastic rotamer library of ligands. J Chem Inf Model 2010, 50: 1623–1632. 10.1021/ci100218tPubMed CentralView ArticlePubMedGoogle Scholar
- Rutherford K, Le Trong I, Stenkamp RE, Parson WW: Crystal structures of human 108 V and 108 M catechol O-methyltransferase. J. Mol. Biol. 2008, 380: 120–130. 10.1016/j.jmb.2008.04.040View ArticlePubMedGoogle Scholar
- Kopin IJ, Zukowska-Grojec Z, Bayorh MA, Goldstein DS: Estimation of intrasynaptic norepinephrine concentrations at vascular neuroeffector junctions in vivo. Naunyn Schmiedebergs Arch Pharmacol 1984, 325: 298–305. 10.1007/BF00504372View ArticlePubMedGoogle Scholar
- Ressler KJ, Nemeroff CB: Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 1999, 46: 1219–1233. 10.1016/S0006-3223(99)00127-4View ArticlePubMedGoogle Scholar
- Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34: 4202–4210. 10.1021/bi00013a008View ArticlePubMedGoogle Scholar
- Garris PA, Ciolkowski EL, Pastore P, Wightman RM: Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 1994, 14: 6084–6093.PubMedGoogle Scholar
- Goldstein DS, Zimlichman R, Stull R, Keiser HR, Kopin IJ: Estimation of intrasynaptic norepinephrine concentrations in humans. Hypertension 1986, 8: 471–475. 10.1161/01.HYP.8.6.471View ArticlePubMedGoogle Scholar
- Mogil JS, Crager SE: What should we be measuring in behavioral studies of chronic pain in animals? Pain 2004, 112: 12–15. 10.1016/j.pain.2004.09.028View ArticlePubMedGoogle Scholar
- Mogil JS: Animal models of pain: progress and challenges. Nat Rev Neurosci 2009, 10: 283–294.View ArticlePubMedGoogle Scholar
- Greenspan JD, Slade GD, Bair E, Dubner R, Fillingim RB, Ohrbach R, Knott C, Mulkey F, Rothwell R, Maixner W: Pain sensitivity risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case control study. J Pain 2011, 12: T61–74. 10.1016/j.jpain.2011.08.006PubMed CentralView ArticlePubMedGoogle Scholar
- Axelrod J, Tomchick R: Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 1958, 233: 702–705.PubMedGoogle Scholar
- Hoffman JL: Chromatographic analysis of the chiral and covalent instability of S-adenosyl-L-methionine. Biochemistry 1986, 25: 4444–4449. 10.1021/bi00363a041View ArticlePubMedGoogle Scholar
- Borchardt RT, Wu Y: S-Aristeromycinyl-L-homocysteine, a Potent Inhibitor of S-Adenosylmethionine-Dependent Transmethylations. J. Med. Chem. 1976, 19: 197–198. 10.1021/jm00223a043View ArticlePubMedGoogle Scholar
- Lin MT, Chandra A, Chi ML, Kau CL: Effects of increasing serotonergic receptor activity in brain on analgesic activity in rats. Exp Neurol 1980, 68: 548–554. 10.1016/0014-4886(80)90108-9View ArticlePubMedGoogle Scholar
- Smith AJ: The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmacol 1998, 12: 407–413. 10.1177/026988119801200413View ArticlePubMedGoogle Scholar
- Messing RB, Lytle LD: Serotonin-containing neurons: their possible role in pain and analgesia. Pain 1977, 4: 1–21.View ArticlePubMedGoogle Scholar
- Lynch ME: Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001, 26: 30–36.PubMed CentralPubMedGoogle Scholar
- Coluzzi F, Mattia C: Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des 2005, 11: 2945–2960. 10.2174/1381612054864993View ArticlePubMedGoogle Scholar
- Mays TA: Antidepressants in the management of cancer pain. Curr Pain Headache Rep 2001, 5: 227–236. 10.1007/s11916-001-0036-8View ArticlePubMedGoogle Scholar
- Wolfe F, Cathey MA, Hawley DJ: A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994, 23: 255–259. 10.3109/03009749409103725View ArticlePubMedGoogle Scholar
- Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39: 1852–1859. 10.1002/art.1780391111View ArticlePubMedGoogle Scholar
- Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112: 191–197. 10.1016/S0002-9343(01)01089-0View ArticlePubMedGoogle Scholar
- Norregaard J, Volkmann H, Danneskiold-Samsoe B: A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995, 61: 445–449. 10.1016/0304-3959(94)00218-4View ArticlePubMedGoogle Scholar
- Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50: 2974–2984. 10.1002/art.20485View ArticlePubMedGoogle Scholar
- Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM: Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136: 432–444. 10.1016/j.pain.2008.02.024View ArticlePubMedGoogle Scholar
- Lee YC, Chen PP: A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 2010, 11: 2813–2825. 10.1517/14656566.2010.507192View ArticlePubMedGoogle Scholar
- Khare SD, Caplow M, Dokholyan NV: The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2004, 101: 15094–15099. 10.1073/pnas.0406650101PubMed CentralView ArticlePubMedGoogle Scholar
- Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al.: Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004, 75: 807–821. 10.1086/425589PubMed CentralView ArticlePubMedGoogle Scholar
- Liang K, Zeger SL: Longitudinal data analysis using generalized linear models Biometrika. 1986, 73: 13–22.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.